Enzyme Replacement Therapy in a Feline Model of MPS VI: Modification of Enzyme Structure and Dose Frequency

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Pediatric Research

• Publication date

  2000-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1203/00006450-200006000-00010PMID 10832731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distribution and analysis of surface charge on brain endothelium in vitro and in situ

  2004cited by this paper
• Recombinant caprine 3H-[N-Acetylglucosamine-6-Sulfatase] and human 3H-[N-Acetylgalactosamine-4-Sulfatase]

  1998cited by this paper
• Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.

  1998cited by this paper
• Recombinant human sulphamidase: expression, amplification, purification and characterization.

  1998cited by this paper
• Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.

  1997cited by this paper
• Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Expression, purification and characterization of recombinant caprine N-acetylglucosamine-6-sulphatase.

  1997cited by this paper
• Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.

  1996cited by this paper
• Polyamine Modification Increases the Permeability of Proteins at the Blood‐Nerve and Blood‐Brain Barriers

  1996cited by this paper
• Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

  1996cited by this paper
• Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B).

  1996cited by this paper
• Expression, purification and characterization of recombinant human N-acetylgalactosamine-6-sulphatase.

  1995cited by this paper
• Human acetyl-coenzyme A:alpha-glucosaminide N-acetyltransferase. Kinetic characterization and mechanistic interpretation.

  1995cited by this paper
• Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome

  1995cited by this paper
• Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts.

  1994cited by this paper
• Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells

  1994cited by this paper
• Enzyme replacement in a canine model of Hurler syndrome.

  1994cited by this paper
• Characterization of phorbol ester-stimulated serine phosphorylation of the human insulin receptor.

  1994cited by this paper
• Enzyme replacement therapy for murine mucopolysaccharidosis type VII.

  1994cited by this paper
• Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells.

  1994cited by this paper
• Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells.

  1994cited by this paper
• Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme.

  1993cited by this paper
• Human alpha-L-iduronidase. Catalytic properties and an integrated role in the lysosomal degradation of heparan sulphate.

  1992cited by this paper
• A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulphatases.

  1992cited by this paper
• Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase.

  1992cited by this paper
• Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

  1991cited by this paper
• Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase.

  1991cited by this paper
• Purification and Partial Characterization of α-N-Acetylglucosaminidase from Human Liver

  1991cited by this paper
• Regional blood-brain barrier transport of cationized bovine serum albumin in awake rats.

  1991cited by this paper
• Human alpha-L-iduronidase: cDNA isolation and expression.

  1991cited by this paper
• Human liver N-acetylgalactosamine 6-sulphatase. Purification and characterization.

  1991cited by this paper
• Purification and partial characterization of alpha-N-acetylglucosaminidase from human liver.

  1991cited by this paper
• Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and C.

  1990cited by this paper
• Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B.

  1990cited by this paper
• Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector.

  1990cited by this paper
• Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

  1990cited by this paper
• Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA.

  1990cited by this paper
• Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties.

  1989cited by this paper
• Sanfilippo D syndrome: estimation of N-acetylglucosamine-6-sulfatase activity with a radiolabeled monosulfated disaccharide substrate.

  1989cited by this paper
• Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein.

  1989cited by this paper
• Cloning, sequencing, and expression of cDNA for human beta-galactosidase.

  1988cited by this paper
• Cloning, sequencing, and expression of cDNA for human -galactosidase

  1988cited by this paper
• Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.

  1988cited by this paper
• Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

  1987cited by this paper
• Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

  1987cited by this paper
• Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values.

  1987cited by this paper
• Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.

  1987cited by this paper
• Cloning, sequencing, and expression of cDNA for human beta-glucuronidase.

  1987cited by this paper
• Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions.

  1986cited by this paper
• A rapid four column purification of 2-deoxy-D-glucoside-2-sulphamate sulphohydrolase from human liver.

  1983cited by this paper
• Study of protein characteristics that influence entry into the cerebrospinal fluid of normal mice and mice with encephalitis.

  1982cited by this paper
• Enzymatic diagnosis of the mucopolysaccharidoses Experience of 96 cases diagnosed in a five‐year period

  1982cited by this paper
• Physiological function of connective tissue polysaccharides.

  1978cited by this paper
• Transport of solutes through cartilage: permeability to large molecules.

  1976cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• GM1 ganglioside beta-galactosidase. A. Purification and studies of the enzyme from human liver.

  1974cited by this paper
• Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation.

  1971cited by this paper
• A method for the quantitative modification and estimation of carboxylic acid groups in proteins.

  1967cited by this paper
• PURIFICATION AND PROPERTIES OF HUMAN LIVER BETA-GLUCURONIDASE.

  1965cited by this paper
• Ion-exchange reactions between cartilage and various cations.

  1960cited by this paper

• Arylsulfatase B induces melanoma apoptosis by the ubiquitin ligase COP1

  2025cites this paper
• Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10‐year prospective study

  2023cites this paper
• Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats

  2018cites this paper
• Mucopolysaccharidosis Type VI in a Great Dane Caused by a Nonsense Mutation in the ARSB Gene

  2018cites this paper
• Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.

  2016cites this paper
• Therapeutic approaches to Lysosomal Storage Disorders: the example of Pompe Disease

  2014cites this paper
• Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

  2014cites this paper
• Therapies for Lysosomal Storage Diseases

  2013cites this paper
• Rhodamine B and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose (F-GlcNAc) inhibit chondroitin/dermatan and keratan sulphate synthesis by different mechanisms in bovine chondrocytes.

  2012cites this paper
• Human sulfatase transiently and functionally active expressed in E. coli K12

  2010cites this paper
• Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice

  2010cites this paper
• Glicosilación de las enzimas humanas iduronato 2-sulfato-sulfatasa (IDS) y galactosamina 6-sulfato sulfatasa (Galns) expresadas en Pichia pastoris

  2010cites this paper
• Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.

  2010cites this paper
• Galsulfase: enzyme therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)

  2010cites this paper
• Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

  2009cites this paper
• Análisis genético y molecular del síndrome de Maroteaux-Lamy

  2008cites this paper
• Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy

  2008cites this paper
• Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.

  2007cites this paper
• Management Guidelines for Mucopolysaccharidosis VI

  2007cites this paper
• Animal models for mucopolysaccharidosis disorders and their clinical relevance

  2007cites this paper
• Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase.

  2007cites this paper
• Substrate deprivation as a novel therapy for the mucopolysaccharidoses.

  2007cites this paper
• Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage diseases.

  2006cites this paper
• Bone marrow transplantation for lysosomal storage disorders

  2006cites this paper
• Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage diseases

  2006cites this paper
• Intra-Articular Enzyme Administration for Joint Disease in Feline Mucopolysaccharidosis VI: Enzyme Dose and Interval

  2006influential citation
• Galsulfase: enzyme-replacement therapy for mucopolysaccharidosis Type VI (Maroteaux–Lamy syndrome)

  2006cites this paper
• Joint and Bone Disease in Mucopolysaccharidoses VI and VII: Identification of New Therapeutic Targets and BioMarkers Using Animal Models

  2005cites this paper
• Therapy of Lysosomal Storage Diseases

  2005cites this paper
• Investigations on Mannose-6-Phosphate Receptor Mediated Protein Uptake

  2005cites this paper
• Mucopolysaccharidose de type III

  2005cites this paper
• Enzyme replacement and enhancement therapies for lysosomal diseases

  2004cites this paper
• Gene therapy for lysosomal storage diseases: the lessons and promise of animal models

  2004cites this paper
• Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

  2003cites this paper
• Comparison of Fluidized Bed and Ultrasonic Cell‐Retention Systems for High Cell Density Mammalian Cell Culture

  2003cites this paper
• Gene Transfer Strategies for Correction of Lysosomal Storage Disorders

  2003cites this paper
• Cardiac and Ocular Pathologies in a Mouse Model of Mucopolysaccharidosis Type VI

  2003cites this paper
• Gene therapy for lysosomal storage disorders

  2003cites this paper
• The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.

  2003cites this paper
• Type I Mucopolysaccharidosis Type II Mucopolysaccharidosis Type III A Mucopolysaccharidosis Type III B Mucopolysaccharidosis Type VI Mucopolysaccharidosis Type

  2003cites this paper
• Recognition and diagnosis of lysosomal storage diseases in the cat and dog.

  2002cites this paper
• Animal models for mucopolysaccharidoses and their clinical relevance

  2002cites this paper
• Sequencing the Genome of the Domestic Cat Felis catus

  2002cites this paper
• Chemoenzymatic preparation of dermatan sulfate oligosaccharides as arylsulfatase B and α-L-iduronidase substrates

  2000cites this paper